THE ACCUCINCH® VENTRICULAR RESTORATION SYSTEM

As the only completely transcatheter therapy to treat the enlarged left ventricle, the AccuCinch Ventricular Restoration System is a fundamentally different and innovative device-based therapy designed to improve the structure and function of the heart.

For heart failure patients with reduced ejection fraction (HFrEF) who remain symptomatic despite guideline-directed medical therapy, early feasibility clinical data suggests that the AccuCinch System may provide a new treatment option by filling the gap between medication or cardiac resynchronization therapy, and left ventricular assist devices (LVADs) or a heart transplant.

ACCUCINCH SYSTEM GOALS

  • Reduce the size of the left ventricle and reduce wall stress
  • Provide support and strength to the left ventricle
  • Initiate a biological process of reverse remodeling to improve myocardial contractility and overall cardiac function

Improved
Quality of Life

Improved Functional Capacity

Improved Life Expectancy

HOW THE ACCUCINCH SYSTEM WORKS

ACCESS

  • The left ventricle (LV) is accessed through the aortic valve using the AccuCinch Guide catheter
  • A guide wire is then placed within the LV, behind the chordae, using the AccuCinch NavCath

DELIVERY

  • The AccuCinch TracCath is advanced over the guide wire to provide a template for implant delivery
  • During AccuCinch Implant delivery, a series of anchors, each separated by a spacer to distribute force, are delivered over a cable are placed into the LV wall

CINCH

  • The AccuCinch Implant is then cinched and secured with a nitinol lock to reduce the size of the LV

PROMISING FINDINGS TO DATE

Early feasibility clinical data has demonstrated that the AccuCinch System may improve quality of life, improve functional capacity, and enable reverse remodeling in symptomatic heart failure patients with reduced ejection fraction (HFrEF).

Watch Dr. Ulrich Jorde, Professor of Medicine, Albert Einstein College of Medicine, and section head of Heart Failure, Cardiac Transplantation and Mechanical Circulatory Support at Montefiore Health System in New York present the 12-Month Outcomes of the AccuCinch Ventricular Restoration System at the Technology & Heart Failure Therapeutics Conference (THT 2022)

THE CORCINCH-HF STUDY

Patients are currently being enrolled in The CORCINCH-HF Study, a prospective, randomized, open-label, multicenter, international, clinical safety and efficacy investigation.

FOOTNOTES

1 Mozzafarian D, Benjamin EJ, Go AS, et al. on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation. 2016;133:e38-e360.
Koelling T, et al. American Heart Journal. Volume 144, Issue 3, Sep 2002, Pages 524-529. Prognostic significance of mitral regurgitation and tricuspid regurgitation in patients with left ventricular systolic dysfunction.

To Learn More

GET IN TOUCH